Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties PLC
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties PLC
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties PLC
Form 8.3 - The Vanguard Group, Inc.: Aviva PLC
Form 8.3 - The Vanguard Group, Inc.: Aviva PLC
Form 8.3 - The Vanguard Group, Inc.: Aviva PLC
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Primary Health Properties plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Genel Energy PLC: Entry into Exploration and Production Sharing Agreement in Oman
Genel Energy PLC: Entry into Exploration and Production Sharing Agreement in Oman
Genel Energy PLC: Entry into Exploration and Production Sharing Agreement in Oman
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference


Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will

Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Halfords Group PLC: Total Voting Rights
Halfords Group PLC: Total Voting Rights
Halfords Group PLC: Total Voting Rights
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update


Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results

Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Spirent Helps CEWiT Drive India’s Bharat 6G Vision with Advanced Testing and Emulation
Spirent Helps CEWiT Drive India’s Bharat 6G Vision with Advanced Testing and Emulation


Spirent Communications plc (LSE:SPT), the leading provider of test and assurance solutions for next-generation devices and networks, today announced its collaboration with the Centre of Excellence

Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Nanoco präsentiert auf kommenden Branchenkonferenzen
Nanoco präsentiert auf kommenden Branchenkonferenzen


Die Nanoco Group PLC (LSE: NANO), ein weltweit führendes Unternehmen in der Entwicklung und Herstellung von cadmiumfreien Quantenpunkten und anderen fortschrittlichen Nanomaterialien, verstärkt

Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc